Acute to Chronic Electro-Clinical Manifestations of Neuro-COVID and the Long-Haul Consequences in People With Epilepsy: A Review

Anna Milan 1, Philippe Salles 2, Carolina Pelayo 3, Reinaldo Uribe-San-Martin 4

1. Epilepsy, Liga Chilena Contra La Epilepsia, Santiago, CHL
2. Movement Disorders, Centro de Trastornos del Movimiento (CETRAM), Santiago, CHL
3. Neuroimmunology, Pontificia Universidad Católica de Chile, Santiago, CHL
4. Epilepsy, Pontificia Universidad Católica de Chile, Santiago, CHL

Corresponding author: Anna Milan, milan.anna@gmail.com

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection can involve the central nervous system (CNS). Acute symptomatic seizures or epileptiform discharges have not been commonly reported in patients with altered mental status related to coronavirus disease 2019 (COVID-19) infection. However, long-term neurological symptoms have been reported after COVID-19 infection (i.e., brain fog, cognitive complaints, and confusion), suggesting chronic encephalopathy. People with epilepsy (PWE) have been specifically affected by the COVID-19 pandemic, with changes in their seizure frequency, quality of life, health care accessibility, and medication interactions. This narrative review highlights possible pathophysiological mechanisms of COVID-19 on the brain, related to short- and long-term epileptiform activity and the impact of this infection on PWE.

Keywords: people with epilepsy, brain fog, eeg, long-haul covid, encephalitis, covid-19, seizures, epilepsy

Introduction and Background

Coronavirus disease 2019 (COVID-19) has affected more than 508 million people, causing more than 6 million deaths, as reported by World Health Organization (https://covid19.who.int). In addition to respiratory symptoms, this disease compromises the central nervous system (CNS) [1]. Acutely, patients may manifest mild to severe encephalitis, with unspecific symptoms ranging from dizziness, headache, and altered mental status. Loss of smell or taste has been associated with CNS involvement [2,3]. Clinically, about one-fourth of patients manifest CNS symptoms in the acute phase [1].

According to the International League Against Epilepsy and the International Bureau for Epilepsy, epilepsy is a brain disease characterized by an enduring predisposition to generate seizures and the neurobiological, cognitive, psychological, and social consequences of seizure recurrences [4]. It comprises an essential fraction of the worldwide disease burden, accounting for about 46 million people, 80% of whom are from low-income countries [5]. The effect of this pandemic in people with epilepsy (PWE) is relevant.

How and for how long SARS-COV-2 CNS infection affects the brain is an open debate[6]. It is too early to determine if remote symptomatic seizures will increase in patients with a history of COVID-19 or if non-provoked seizures will increase after the pandemic.

This narrative review discusses the potential pathophysiological mechanisms of COVID-19 on the brain, particularly in terms of direct CNS invasion, inflammatory response, and autoimmune responses. We discuss how CNS involvement may occur, its possible long-term consequences, and the impact the pandemic has had specifically in PWE.

Acute SARS-COV-2 related encephalopathy/encephalitis

Our current understanding of COVID-19 CNS involvement includes thromboembolic events resulting in hypoxia [7], blood-brain barrier alterations, and cerebral damage secondary to neuro-invasion and neuroinflammation [8]. Cytokine storm is a well-known pathophysiological mechanism of COVID-19, more common in adults over 65. When cytokines cross the brain-blood barrier, the astrocytes and microglia elicit a neuroinflammatory response, increasing oxidative stress and glutamate levels, leading to an excitotoxic environment with neuronal loss and parenchymal damage [9].

Among patients with COVID-19, 7.5 to 31% have presented with acute encephalopathy, manifesting altered mental status (i.e., amnesia, disorientation, behavioral changes, or sleep disorders) without evidence of encephalitides nor abnormalities on neuroimaging [3,10]. Most of these cases manifest a viral prodrome from 1 to 21 days [11].
A positive SARS-COV-2 genome sequencing or high titers of IgM antibodies against SARS-COV-2 spike protein in cerebrospinal fluid (CSF) samples have supported the diagnosis of COVID-19 encephalitis [11-14]. However, most cases of COVID-19-related encephalitis have shown no evidence of SARS-COV-2 in CSF [15]; polymerase chain reaction (PCR) analysis in CSF of 238 severe COVID-19 patients with neurological symptoms was positive for SARS-CoV-2 in only 6% [16]. Antibody testing in CSF is an alternative to making this diagnosis [17]. Besides, cases cataloged as COVID-19-related encephalitis with negative results for both tests have been reported [10]. Other authors have made the diagnosis of COVID-19-related encephalitis with no CSF testing [11,14]. The heterogeneity in these approaches makes interpretation challenging.

Individuals with COVID-19 encephalitis have shown poor responses to antiviral agents (i.e., remdesivir); however, a favorable response to rituximab may suggest an autoimmune setting [14,18]. A parallel with other well-known viral CNS infections associated with para-infectious autoimmune disorders might help to elucidate COVID-19 encephalitis pathophysiology. For instance, herpetic encephalitis has been related to anti-NMDAR encephalitis [19]. A comparison between herpetic encephalitis, anti-NMDAR-encephalitis, and COVID-19-related encephalitis is shown in Table 1. There is evidence of intrathecal pro-inflammatory cytokine production [12], mainly interleukin (IL)-6 and IL-8, in COVID-19 encephalitis [20]. Similarly, tumor necrosis factor (TNF)-alpha, IL-6, interferon (IFN)-alpha, IL-10, chemokine ligand (CXCL)13, and CXCL10 are all sensitive CSF markers of enteroviral encephalitis and anti-NMDAR encephalitis, corroborating CNS inflammation [21]. Proteinorrachia is common in patients with COVID-19 encephalitis, with occasionally lymphocytic pleocytosis [22], but is rarely seen in anti-NMDAR encephalitis.
|                              | COVID-19 encephalitis | Herpetic encephalitis | Anti-NMDAR Autoimmune encephalitis |
|------------------------------|-----------------------|-----------------------|------------------------------------|
| **Age at presentation**      | > 50-years-old        | > 50-years-old        | Adolescent/young adults            |
| **Associated comorbidities** | Hypertension, diabetes, or obesity | No specific associations | Ovarian teratoma (>50%) |
| **Altered mental status**    | Common                | Common                | Common                             |
| **Neuro-psychiatric features** | Less common          | Frequent behavioral changes | Prominent behavioral/ personality changes, psychosis |
| **Cognitive changes**        | Long term, but not acutely | At presentation or long term | Prominent. At presentation or long term |
| **Prodrome**                 | Viral-like prodrome   | Simultaneous          | Viral-like prodrome                 |
| **Other neurological symptoms** | Movement disorders, autonomic manifestations | Headache Speech disturbances | Movement disorders, speech disturbances, autonomic manifestations |
| **Seizures**                 | Less likely           | Frequent              | Frequent                            |
| **Laboratory findings**      | Lymphopenia Low platelets High urea levels | Leukocytosis Neutrophilia Hyponatremia | |
| **Findings on EEG**          | Non-specific slowing in 90 to 100% of patients | Uni-or-bilateral periodic sharp waves or attenuation of amplitude, focal, generalized slow waves or epileptiform discharges. | Beta:Delta ratio (BDR), may be specific Extreme Delta brush (30% sensitivity) Unspecific slowing in 90% Continuous rhythmic activity during the catatonic phase |
| **Findings on Brain MRI**    | Infrequent hyperintensities in different regions | Frequent temporal lobe involvement | Infrequent hyperintensities in different regions |
| **Findings on CSF**          | Proteinorrachia Lymphocitic pleocytosis Inflammatory cytokines found on CSF | Proteinorrachia Lymphocitic pleocytosis Hypoglycorrachia (25%) Inflammatory cytokines found on CSF | Unfrequently proteinorrachia and Lymphocytic pleocytosis Oligoclonal bands (36%) |
| **Mortality**                | 22%                   | 15-30%                | 5 to 10%                           |
| **Long term Prognosis**      | Unknown               | 69% sequelae          | 75% recover or have mild sequelae   |

**TABLE 1: Clinical features of patients affected by COVID-19-related encephalitis, Herpetic encephalitis, or anti-NMDAR encephalitis.**

References: Garg et al., 2021 [10]; Tandon et al., 2021 [22]; Barry et al., 2015 [23]; Sili et al., 2014 [24]

The most frequent findings in brain autopsies of people with severe COVID-19 were ischemic changes and reactive Alzheimer type II astrocytes. However, no specific results suggestive of meningitis or encephalitis were reported. Only five out of 18 patients had a positive SARS-CoV-2 PCR in this study [25].

Although infrequent, SARS-CoV-2-associated MRI changes can affect any part of the brain, with preferential temporal lobe involvement [11]. Leukoencephalopathy, acute necrotizing encephalitis, mild encephalitis/encephalopathy with a reversible splenial lesion (MERS), or posterior reversible encephalopathy syndrome (PRES) have been reported [3,26].
Review

Short and long-term effects of COVID-19 in relation to epilepsy

1. Electroencephalogram (EEG) Features During the Acute Phase

1.1 Non-epileptiform EEG findings in patients with acute COVID-19. Acute EEG findings of critically ill patients with a COVID-19 diagnosis are non-specific 

[27]. For instance, a retrospective series of 19 patients undergoing continuous scalp EEG described non-convulsive seizures in 10.5% of patients and epileptiform discharges (including the two patients with seizures) in 15.7% of patients. Patients with altered mental status showed generalized polymorphic delta slowing in over 80% of their records. Absent background was seen in 42.1% of patients, slow background in 47.4% of patients, and a normal background was noted in 10.5% of all patients [28].

Over 1/3 of patients in a cohort of 22 had generalized periodic discharges (GPDs), primarily with triphasic morphology [28]. A systematic review noted that only 3.4% of 117 patients with COVID-19 connected to continuous scalp EEG due to altered mental status or seizure-like activity had a normal EEG. Over 60% of patients presented with generalized slowing and less than 8% with focal slowing [27]. Only 7.3% of patients had GPDs or lateralized periodic discharges in this review. Bilateral independent periodic discharges (BiPDs) were seen in only one patient, evolving into status epilepticus (SE) [27].

Among 36 in-hospital patients undergoing COVID-19 [27], 40 non-continuous scalp EEGs were performed due to delayed awakening after discontinued sedation or confusion. Almost 60% had either normal or mildly altered EEGs. No specific pathognomonic feature was noted [29].

As with previous studies, 19 out of 1574 patients with laboratory-confirmed COVID-19 required a scalp EEG [28]. Severe EEG abnormalities consistent with encephalopathy were seen in 13 of them. However, no periodic discharges or subclinical seizures were noted. Remarkably, five patients with severe encephalopathy showed an alpha coma pattern not attributed to sedation but related to the peak severity of COVID-19, between days 14 and 27 of disease. No difference in outcome was seen compared to those with severe encephalopathy and different EEG patterns [30].

Since alpha coma is generally a transient acute phenomenon, its late occurrence in patients with COVID-19 and normal neuroimaging might be secondary to neurotropism of COVID-19 and delayed CNS invasion [31].

A comparative analysis of quantitative EEG revealed significant differences in bandwidths between COVID-19 encephalopathy and other disorders. Patients with toxic or infectious encephalopathy had mainly delta frequencies within all lobes; in contrast, patients with post anoxic injuries due to cardiorespiratory arrest were seen to have higher rates of beta frequencies. COVID-19 was always in the middle ground for all bandwidth frequencies compared to these other pathologies [32]. Therefore, COVID-19 encephalopathy should not be considered only infectious nor strictly vascular.

A prospective Chilean study demonstrated that "requiring an EEG at the third week of COVID-19 infection" was an independent risk factor for elevated mortality. This was possibly related to the hyperinflammatory phase, cytokine storm, and acute respiratory distress syndrome [33].

1.2 Intercital epileptiform discharges and non-convulsive SE in COVID-19 patients as compared to other encephalopathies. Epileptiform discharges are not frequent in patients with COVID-19 presenting with altered mental status [27]. Only 34 out of 177 COVID-19 patients monitored with EEG had interictal discharges (19.2%) in a systematic review, of whom two had a prior history of epilepsy. SE was noted in 4.5% of patients, and only five cases (2.8% of patients) had a non-convulsive status epilepticus (NCSE) [27]. Similarly, NCSE prevalence was 4.2% in a cohort of 62 patients suffering from severe COVID-19 [31]. The most frequent EEG finding was generalized continuous slowing. Although interictal activity was seen in almost 20% out of 94 EEGs analyzed from these 62 patients; the prevalence of SE was not different from other series [33].

A recent meta-analysis found EEG epileptiform discharges in 22.4% of patients with no history of epilepsy or seizures and up to 59.5% in those who had a history of epilepsy. Seizures were seen in no more than 2% of patients, and SE was seen in less than 1% of all patients [34]. Compared with herpetic encephalitis, with an incidence of close to 30%, the frequency of NCSE is much lower in COVID-19 [35]. The prevalence of SE in severe COVID-19 cases has been estimated to be as low as 5% [36].

In a recent multicenter retrospective study [37] including 4100 patients hospitalized with COVID-19, only 100 patients (2.68%) required an EEG during admission. As expected, most patients that required EEG needed mechanical ventilation. Almost one-fourth of these patients had a new-onset seizure, including 7% who presented with SE. Less than 15% of patients with seizures had a history of epilepsy [37]. A recent systematic review found that 27 out of 47 (57.4%) patients presented with SE after COVID-19 respiratory/gastrointestinal symptoms, with fewer patients (14.9%) developing SE as the first manifestation. Seventeen patients (36.2%) met the diagnostic criteria for New-onset Refractory SE (NORSE) [38].
Many studies have implied that inflammation activation is inextricably linked to cognitive dysfunction. 5 Dioxygenase-1 activation, and oxidative stress, blood-brain barrier (BBB) disruption, microglia activation, neurotransmission alteration, indoleamine 2,3-dioxygenase-1 activation, and oxidative stress are underpinning pathogenetic mechanisms for depressive psychopathology observed in mood disorders in the absence of known triggering factors. They are currently investigated as higher immune and inflammatory set points with greater circulating biomarkers of inflammation.

HIV-associated neurocognitive disorders dysregulated cytokine expression and production, resulting in synaptodendritic dysfunction, as described in infections.

As described with other viruses, a neuropathogenic mechanism of cognitive impairment might be due to chronic brain infection and release of viral proteins that harm nearby neurons and other cells. An indirect route could be possible through macrophage proliferation, microglial/astroglial activation, and dysregulated cytokine expression and production, resulting in synaptodendritic dysfunction, as described in HIV-associated neurocognitive disorders.

Higher immune and inflammatory set points with greater circulating biomarkers of inflammation are observed in mood disorders in the absence of known triggering factors. They are currently investigated as underpinning pathogenetic mechanisms for depressive psychopathology. Peripheral cytokines involved in the host anti-viral response may elicit psychiatric and neurocognitive symptoms by precipitating inflammation in the peripheral and CNS. Inflammation is known to be associated with depression inducing blood-brain barrier (BBB) disruption, microglia activation, neurotransmission alteration, indoleamine 2,3-dioxygenase-1 activation, and oxidative stress.

Many studies have implied that inflammation activation is inextricably linked to cognitive dysfunction.
suggesting a primary role of IL-1β, IL-6, IL-18, and TNF-α. Recently, elevated NLR was described in mild cognitive impairment, while platelet/lymphocyte ratio and SII were associated with the risk of dementia in the general population [52]. Unfortunately, targeted and long-term studies to test these hypotheses are warranted. It is necessary to standardize proper neurocognitive batteries to evaluate these patients over time and separate the cognitive evaluation from psychological or psychiatric symptoms.

3.3 “Brain-Fog”, and how people with epilepsy (PWE) have been affected by COVID-19: Current knowledge suggests that viral infections can trigger chronic inflammation and aberrant immune responses, causing long-lasting neuropsychiatric syndromes involving cognitive, affective, and behavioral symptoms from weeks to years following acute infection [51]. People with chronic illnesses are most at risk [53].

PWE may have diverse factors contributing to cognitive and behavioral impairments compared to the general population. These include elements related to the etiology or neuropathology of their epilepsy, history of SE, psychosocial factors such as education opportunities, and antiseizure medication (ASM) [54]. In that respect, ASM has known interactions with other treatments. Treatment with ASM that interact with cytochrome p450 enzymes may generate hepatic problems, which may become exacerbated by severe COVID-19 infection. Similarly, patients with severe COVID-19 disorders may have multi-organ failure that could require adjustment or even change in their ASM [55].

Recently, long-term neurological symptoms of COVID-19 have been divided according to their temporality: (1) subacute, from 4 to 12 weeks beyond the acute phase of COVID-19, and (2) chronic or post COVID-19 syndrome after 12 weeks [56]. The most common abnormalities seen in the latter include fatigue, myalgia, headache, dysautonomia, and cognitive impairment (or brain fog); mimicking fibromyalgia and chronic fatigue syndrome [2].

In a prospective study of 1733 patients in Wuhan, at six months of COVID-19 infection, ~80% reported at least one post-COVID-19 symptom. Fatigue or muscle weakness was reported in 63%, sleep difficulties in 26%, and anxiety or depression in 23% [57].

Although seizures do not seem to be an essential acute complication related to COVID-19 [35,38], people with known epilepsy have seen an increase in seizure frequency since the start of the pandemic [58]. A survey by the ILAE task force showed that this increase in seizure frequency might be multifactorial and includes difficulties accessing healthcare systems, accessing information, difficulty accessing psychological support, and an increase in psychological distress. Barriers to access to the usual health programs included delayed investigation and therapy, appointment cancellations, limited availability of providers, and dissatisfaction with tele-health. Regarding the increase in psychological stress, this same study found that 57.1% of PWE had a K-6 score higher than 13, compared to 14% in a similar cohort surveyed before the pandemic [58].

It is essential to study the effect epilepsy and ASMs may have on long-haul COVID-19. Brain fog is a significant long-term effect of COVID-19 infection. Patients with epilepsy may be using ASM, which could have crucial cognitive side effects. Newer ASMs such as lamotrigine, levetiracetam, and gabapentin have been noted to have fewer cognitive effects when compared to carbamazepine [59]. On the other hand, topiramate has a poor cognitive profile, with an essential impact on verbal fluency [59]. Although levetiracetam seems to be safe from a metabolic and cognitive perspective, its effect from a neuropsychological standpoint could influence the long-term psychiatric disorders noted as part of long haul covid, such as anxiety and depression.

Conclusions

In contrast with other CNS infections, patients with COVID-19 have a lower incidence of acute symptomatic seizures and SE, but long-term neurological symptoms have been noted. Neuropsychiatric symptoms such as depression and neurocognitive impairment have been observed in patients with COVID-19 months after acute infection. Brain fog, confusion, or mild cognitive complaints in the convalescent phase after acute COVID-19 encephalitis suggests chronic encephalopathy. PWE present with distinct elements that may exacerbate cognitive and behavioral impairments compared to the general population. These include but are not limited to the effect of antiseizure medication (ASM) during or after COVID-19 infection.

In patients over 65 years of age with a history of mild cognitive impairment or dementia, SARS-CoV-2 could accelerate underlying neurodegeneration, provoking an exaggerated decline in neuropsychological functions. Although rare, acute symptomatic seizures have also been reported. So far, the incidence of epilepsy after COVID-19 infection is yet to be determined.

Available information on seizure incidence in patients with COVID-19 is scarce. Patient outcomes of those manifesting seizures or SE during acute illness are heterogeneous. Longer follow-up is needed to elucidate the prognosis of acute seizures and SE related to COVID-19 and the risk of developing epilepsy. Regarding patients with prior known epilepsy, the pandemic seems to have had significant effects on quality of life and seizure frequency.
Long-term neurological symptoms linger in patients with a history of COVID-19, with neuropsychiatric symptoms persisting even after three months of infection. Future investigations should focus on determining seizure incidence in patients with COVID-19 and longer follow-up is needed to elucidate the prognosis of acute seizures and SE related to COVID-19 and the risk of developing epilepsy. How COVID-19 may affect patients’ long-term quality of life is still an open question. Standardized cognitive batteries are needed to make a reliable and homogenous neurocognitive assessment and in the laboratory setting would be interesting to assess immunological pathways involved through the identification of different innate and adaptive immunity biomarkers.

Additional Information

Disclosures

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Mao L, Jin H, Wang M, et al.: Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020, 77:683-90. 10.1001/jama Neurol.2020.1127
2. Moghim N, Di Napoli M, Biller J, et al.: The neurological manifestations of post-acute sequelae of sars-cov-2 infection. Curr Neurol Neurosci Rep. 2021, 21:44. 10.1007/s11910-021-01130-1
3. Shanflan-Dorange M, Huot P, Osherov M, et al.: Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. J Neurol Sci. 2020, 417:117085. 10.1016/j.jns.2020.117085
4. Fisher RS, Van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel Jr J: Response: Definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005, 46:1701-2. 10.1111/j.1528-1167.2005.00273_4.x
5. Beghi E, Feigin V, Caso V, Santalucia P, Logroscino G: COVID-19 infection and neurological complications: present findings and future predictions. Neuroepidemiology. 2020, 54:364-9. 10.1159/000509891
6. Kuroda N: Epilepsy and COVID-19: updated evidence and narrative review. Epilepsy Behav. 2021, 116:107785. 10.1016/j.yebeh.2021.107785
7. Siddiqi HK, Libby P, Rickler PM: COVID-19 - a vascular disease. Trends Cardiovasc Med. 2021, 31:1-5. 10.1016/j.tcm.2020.10.005
8. Johansson A, Mohrned MS, Moulin TC, Schöth HB: Neurological manifestations of COVID-19: a comprehensive literature review and discussion of mechanisms. J Neuromunnd. 2021, 358:57768. 10.1016/j.neuromund.2021.358.57768
9. Chen Z, Zhong D, Li G: The role of microglia in viral encephalitis: a review. J Neuroinflammation. 2019, 16:76. 10.1186/s12974-019-1443-2
10. Garg RK, Paiwall VK, Gupta A: Encephalopathy in patients with COVID-19: a review. J Med Virol. 2021, 93:206-22. 10.1002/jmv.26207
11. Huo L, Xu KL, Wang H: Clinical features of SARS-CoV-2-associated encephalitis and meningitis amid COVID-19 pandemic. World J Clin Cases. 2021, 9:1058-78. 10.12998/wjcc.v9.i5.1058
12. Benamer E, Agarwal A, Auld SC, et al.: Encephalopathy and encephalitis associated with cerebrospinal fluid cytokine alterations and coronavirus disease, Atlanta, Georgia, USA, 2020. Emerg Infect Dis. 2020, 26:2016-21. 10.3201/ed2009.202122
13. Al-Sarraj S, Troakes C, Hanley B, et al.: Invited review: the spectrum of neuropathology in COVID-19. Neuropathol Appl Neurobiol. 2021, 47:3-16. 10.1111/man.12667
14. Haidar A, Siddiqua A, Ali N, Dhallu M: COVID-19 and the brain: acute encephalitis as a clinical manifestation. Cureus. 2020, 12:e10784. 10.7759/cureus.10784
15. Espindola OM, Siqueira M, Soares CN, et al.: Patients with COVID-19 and neurological manifestations show undetectable SARS-CoV-2 RNA levels in the cerebrospinal fluid. Int J Infect Dis. 2020, 96:567-9. 10.1016/j.ijid.2020.05.123
16. Lewis A, Frontera J, Placantonakis DG, Lighter J, Galetta S, Balcer L, Melmed KR: Cerebrospinal fluid in COVID-19: a systematic review of the literature. J Neurol Sci. 2021, 421:117316. 10.1016/j.jns.2021.117316
17. Hu WT, Howell JC, Ozturk T, et al.: Antibody profiles according to mild or severe SARS-CoV-2 infection, Atlanta, Georgia, USA, 2020. Emerg Infect Dis. 2020, 26:2974-8. 10.3201/eid2612.200334
18. Ali MJ, Hanif M, Haidar MA, et al.: Treatment options for COVID-19: a review. Front Med (Lausanne). 2020, 7:480. 10.3389/fmed.2020.00480
19. Armangue T, Spatola M, Vlasea A, et al.: Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018, 17:760-72. 10.1016/S1474-4422(18)30244-8
20. Pilotta A, Oddolini S, Masciocchi S, et al.: Steroid-responsive encephalitis in coronavirus disease 2019. Ann Neurol. 2020, 88:423-7. 10.1002/ana.25783
21. Kothur K, Wenholt L, Mohammad SS, et al.: Utility of CSF cytokine/chemokines as markers of active intrathecal inflammation: comparison of demyelinating, anti-NMDAR and enteroviral encephalitis. PLoS One. 2016, 11:e0161656. 10.1371/journal.pone.0161656
22. Tandon M, Kataria S, Patel J, et al.: A comprehensive systematic review of csf analysis that defines neurological manifestations of COVID-19. Int J Infect Dis. 2021, 104:390-7. 10.1016/j.ijid.2021.01.002
23. Barry H, Byrne S, Barrett E, Murphy KC, Cotter DR. Anti-N-methyl-d-aspartate receptor encephalitis: review of clinical presentation, diagnosis and treatment. BJPsych Bull. 2015, 39:19-23. 10.1192/bpb.bp.113.045518

24. Sill U, Kayar A, Meri A. Herpes simplex virus encephalitis: clinical manifestations, diagnosis and outcome in 116 adult patients. J Clin Virol. 2014, 60:112-8. 10.1016/j.jcv.2014.03.010

25. Hooper JE, Paderka RF, Dolhnikoff M, et al. A postmortem portrait of the coronavirus disease 2019 (COVID-19) pandemic: a large multi-institutional autopsy survey study. Arch Pathol Lab Med. 2021, 125:529-35. 10.5858/arpa.2020.0786-SA

26. Agawal S, Jain R, Dogra S, et al. Cerebral microbleeds and leukoencephalopathy in critically ill patients with COVID-19. Stroke. 2020, 51:2649-55. 10.1161/STROKEAHA.120.03940

27. Roberto KT, Espiritu AI, Fernandez ML, Gutierrez JC. Electroencephalographic findings in COVID-19 patients: a systematic review. Seizure. 2020, 82:17-22. 10.1016/j.seizure.2020.09.007

28. Louis S, Dhawan A, Newey C, Nair D, Jeel H, Hantsu S, Punia V. Continuous electroencephalography characteristics and acute symptomatic seizures in COVID-19 patients. Clin Neurophysiol. 2020, 131:2651-6. 10.1016/j.clinph.2020.08.003

29. Petrescu AM, Tausigg D, Bouilleret V. Electroencephalogram (EEG) in COVID-19: a systematic retrospective study. Neurophysiol Clin. 2020, 50:155-65. 10.1016/j.neucli.2020.06.001

30. Koutroumanidis M, Groteckie J, Sharma S, Whelan A, Tan SV, Glover G. Alpha coma EEG pattern in patients with severe COVID-19 related encephalitis. Clin Neurophysiol. 2021, 132:218-25. 10.1016/j.clinph.2020.09.008

31. Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021, 12:698169. 10.3389/fmicb.2021.698169

32. Pastor J, Vega-Zelaya L, Martin Abad E. Specific EEG encephalopathy pattern in SARS-CoV-2 patients. J Clin Med. 2020, 9:3390/cm0951545

33. Skorin I, Carrillo R, Perez CP, Sanchez N, Parra J, Troncoso P, Uribe-San-Martin R. EEG findings and clinical prognostic factors associated with mortality in a prospective cohort of inpatients with COVID-19. Seizure. 2020, 83:1-4. 10.1016/j.seizure.2020.10.007

34. Kubota T, Gajera PK, Kuroda N. Meta-analysis of EEG findings in patients with COVID-19. Epilepsy Behav. 2021, 115:107682. 10.1016/j.yebeh.2020.107682

35. Raschillas F, Wolff M, Delatorre F, et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis. 2002, 35:254-60. 10.1086/341405

36. Lovati C, Osio M, Pantoni L. Diagnosing herpes simplex-1 encephalitis at the time of COVID-19 pandemic. Neurol Sci. 2020, 41:1361-4. 10.1007/s10072-020-04461-y

37. Danoum QA, Zilfitzi A, Hill C, et al. Outcomes of seizures, status epilepticus, and EEG findings in critically ill patient with COVID-19. Epilepsy Behav. 2021, 118:107923. 10.1016/j.yebeh.2021.107923

38. Dono F, Nuñez B, Lanzone J, et al. Status epilepticus and COVID-19: a systematic review. Epilepsy Behav. 2021, 118:107887. 10.1016/j.yebeh.2021.107887

39. Anand P, Al-Faraj A, Sader E, et al. Seizure as the presenting symptom of COVID-19: a retrospective case series. Epilepsy Behav. 2020, 112:107335. 10.1016/j.yebeh.2020.107335

40. Khedk EM, Shoyib A, Mohammad M, Saber M. Acute symptomatic seizures and COVID-19: hospital-based study. Epilepsy Res. 2021, 174:106650. 10.1016/j.eplepsyres.2021.106650

41. Kurd M, Hashayva S, Berenson S, Gilboa T. Seizures as the main presenting manifestation of acute SARS-CoV-2 infection in children. Seizure. 2021, 92:89-93. 10.1016/j.seizure.2021.08.017

42. Premraj L, Kannapadi NV, Briggs J, et al. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: a meta-analysis. J Neurol Sci. 2022, 434:120162. 10.1016/j.jns.2022.120162

43. Wright A, Sarangi A, Ibrahim Y. The psychiatric effects of COVID-19 thus far: a review of the current literature. The Southwest Respiratory and Critical Care Chronicles. 2020, 8:17-28.

44. Lallana S, Fonseca E, Restrepo JL, et al. Medium-term effects of COVID-19 pandemic on epilepsy: a follow-up study. Acta Neurol Scand. 2021, 144:99-108. 10.1111/ane.13439

45. Troyer EA, Kohn JN, Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav Immun. 2020, 87:34-9. 10.1016/bbi.2020.04.027

46. Chané-Cuvelas P, Salles-Gándara P, Rojas-Fernandez A, Salinas-Rebolledo C, Milán-Solé A. The potential role of SARS-COV-2 in the pathogenesis of Parkinson's disease. Front Neuro. 2020, 11:1044. 10.3389/neur.2020.01044

47. Levine A, Sacktor N, Becker JT. Studying the neuropsychological sequelae of SARS-CoV-2: lessons learned from 35 years of neuroHIV research. J Neurovirol. 2020, 26:809-23. 10.1177/1079613220943189

48. Grosse L, Carvalho LA, Wijkhuijs AJ, et al. Clinical characteristics of inflammation-associated depression: monocyte gene expression is age-related in major depressive disorder. Brain Behav Immun. 2015, 44:48-56. 10.1016/j.bbi.2014.08.004

49. Gibney SM, Drexhage HA. Evidence for a dysregulated immune system in the etiology of psychiatric disorders. J Neuroimmun Pharmacol. 2013, 8:900-20. 10.1192/pb.bp.113.04542-8

50. Benedetti F, Aggio V, Pratesi ML, Greco G, Furlan R. Neuroinflammation in bipolar depression. Front Psychiatry. 2020, 11:71. 10.3389/fpsyt.2020.00071

51. Mazza MG, Palladini M, De Lorenzo R, et al. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up. Brain Behav Immun. 2021, 94:138-47. 10.1016/bbi.2021.02.021

52. van der Wilik KD, Fari L, Rizopoulos D, et al. Balance between innate versus adaptive immune system and the risk of dementia: a population-based cohort study. J Neuroinflammation. 2019, 16:68. 10.1186/s12974-019-1454-z

53. Kendzierska T, Zhu DT, Gershon AS, Edwards JD, Peixoto C, Robillard R, Kendall CE. The effects of the health system response to the COVID-19 pandemic on chronic disease management: a narrative review.
54. Kwan P, Brodie MJ: Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet. 2001, 357:216-22. 10.1016/S0140-6736(00)0800-X
55. Asadi-Pooya AA, Attar A, Moghadami M, Karimzadeh I: Management of COVID-19 in people with epilepsy: drug considerations. Neurol Sci. 2020, 41:2005-11. 10.1007/s10072-020-04549-5
56. Nalbandian A, Sehgal K, Gupta A, et al.: Post-acute COVID-19 syndrome. Nat Med. 2021, 27:601-15. 10.1038/s41591-021-01283-z
57. Huang C, Huang L, Wang Y, et al.: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021, 397:220-32. 10.1016/S0140-6736(20)32656-8
58. Cross JH, Kwon CS, Asadi-Pooya AA, et al.: Epilepsy care during the COVID-19 pandemic. Epilepsia. 2021, 62:2322-32. 10.1111/epi.17045
59. Hermann B, Meador KJ, Gaillard WD, Cramer JA: Cognition across the lifespan: antiepileptic drugs, epilepsy, or both?. Epilepsy Behav. 2010, 17:1-5. 10.1016/j.yebeh.2009.10.019